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A B S T R A C T
We have synthesized a novel small molecule based on the pyrrolidinone–containing core structure of clausenamide, which is a candidate anti–dementia drug. The
synthetic route yielded multi–gram quantities of an isomeric racemate mixture in a short number of steps. When tested in hippocampal slices from young adult rats
the compound enhanced AMPA receptor–mediated signalling at mossy ﬁbre synapses, and potentiated inward currents evoked by local application of L–glutamate
onto CA3 pyramidal neurons. It facilitated the induction of mossy ﬁbre LTP, but the magnitude of potentiation was smaller than that observed in untreated slices. The
racemic mixture was separated and it was shown that only the (−) enantiomer was active. Toxicity analysis indicated that cell lines tolerated the compound at
concentrations well above those enhancing synaptic transmission. Our results unveil a small molecule whose physiological signature resembles that of a potent
nootropic drug.
1. Introduction
Diseases associated with memory impairment pose a growing
challenge worldwide due to an ageing population (Shah et al., 2016).
The current clinical approach taken to impede cognitive decline in
patients diagnosed with dementia advocates the use of drugs that en-
hance the state of vigilance while improving memory and decision–-
making (Lynch and Gall, 2013; Iwata et al., 2015; Partin, 2015). A
variety of such drugs act by enhancing synaptic pathways from con-
verging cholinergic and dopaminergic systems into the forebrain, or by
raising endogenous catecholamine, orexin, and histamine levels. In
addition, drugs that directly bind to glutamate receptors have been
designed to enable a more selective intervention on excitatory circuits.
In particular, the alpha–amino–3–hydroxy–5–methyl–4–isoxazole pro-
pionic acid (AMPA) receptor represents a major target for drug dis-
covery because of its critical role in synaptic plasticity, the cellular
mechanisms of which are thought to underlie learning and memory,
including long term potentiation (LTP) and long term depression (LTD)
(Huganir and Nicoll, 2013). However, despite decades-long pursuit to
identify positive AMPA receptor modulators (PAMs) and bring them to
clinic, the interest for such compounds is waning, as clinical trials fail to
show eﬃcacy or avoid signiﬁcant toxicity. There is thus urgent need to
develop new compounds that are highly potent at low concentrations,
enhancing target selectivity while minimizing side eﬀects.
Recently, we synthesized a new heterocyclic compound named
BRS–015 (Szulc et al., 2015). BRS–015 is a low molecular weight 5-
membered heterocycle based on the pyrrolidone core related to the
structure of other members of the racetam family. The compound
contains a single chiral centre and is synthesized as a racemic mixture.
BRS–015 is structurally related to the excitotoxin – kainic acid, a potent
AMPA/kainate receptor agonist, and to the natural product clausena-
mide extracted from the shrub Clausena lansium used in Chinese folk
medicine. Clausenamide has been shown to enhance LTP (Feng et al.,
2009) and is thought to possess anti–dementia properties (Chu and
Zhang, 2014; Chu et al., 2016).
Here, we focused on the physiological and toxicology proﬁle of
BRS–015. We asked whether our lead compound modulated synaptic
transmission and synaptic plasticity in the hippocampus. We chose to
study the actions of BRS–015 at hippocampal mossy ﬁbre synapses
because they express the three main types of ionotropic glutamate re-
ceptors whose currents can be studied in isolation in CA3 pyramidal
neurons. These synapses also exhibit a form of LTP whose expression is
independent of N–methyl–D–aspartate (NMDA) receptor activation
(Yamamoto et al., 1992; Zalutsky and Nicoll, 1992; Yeckel et al., 1999;
Reid et al., 2004). Finally, mossy ﬁbres convey a strong excitatory drive
to CA3 pyramidal neurons that is believed to be responsible for pro-
cessing and encoding distinct contextual associations arising in the
dentate gyrus (Jones et al., 2016; Ruiz and Kullmann, 2012; Stella et al.,
2013). We ﬁnd that our small molecule acts as a powerful enhancer of
AMPA receptor–mediated synaptic transmission at mossy ﬁbre sy-
napses. In addition, we demonstrate that a single enantiomer is active
and that the racemic mixture eases mossy ﬁbre LTP induction. Re-
markably, we also ﬁnd it well tolerated by cells, highlighting that it is a
good potential candidate for further pre–clinical development.
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2. Results
2.1. BRS–015 induced enhancement of dentate–CA3 synaptic transmission
BRS–015 was obtained using a novel approach towards the synth-
esis of the core structure of clausenamide via an intramolecular acylal
cyclisation (Szulc et al., 2015) (Supplementary Scheme 1). We ﬁrst
asked whether BRS–015 applied in the region of mossy ﬁbre synapses
had an eﬀect on ﬁeld EPSPs (fEPSPs) recorded in CA3. We positioned a
bipolar tungsten electrode in stratum granulosum in the dentate gyrus
to deliver electrical stimuli every 10 s. The recording pipette was placed
in stratum lucidum in CA3, 100–150 μm away from a pressur-
e–application pipette ﬁlled with BRS–015 (1mM). With this arrange-
ment we avoided manipulating axonal receptors in the vicinity of the
stimulation electrode when delivering the compound. Procedures for
characterization of mossy ﬁbre responses were applied prior to blocking
GABAA and GABAB receptors with picrotoxin (100 μM) and
3–([[[(3,4–dichlorophenyl)methyl]amino]propyl]diethoxymethyl)
phosphinic acid (CGP–524332; 5 μM), respectively (see Materials and
methods). Pressure application of BRS–015 (20 psi, 10 s) in stratum
lucidum reversibly increased the amplitude of evoked fEPSPs (Fig. 1).
After retraction and replacement of the puﬀ pipette, application of
control artiﬁcial cerebro spinal ﬂuid (ACSF) at the same location had no
eﬀect on fEPSP amplitude, arguing against the presence of mechanical
movements. These results demonstrate that the application of BRS–015
in CA3 has a powerful enhancing eﬀect on glutamatergic transmission
originating from the dentate gyrus.
To gain insight into the mechanism involved in the
BRS–015–induced enhancement, we recorded EPSCs in CA3 pyramidal
neurons held in voltage–clamp with a CsCl based pipette solution
(Vholding=−70mV). Paired stimuli (50 Hz) were delivered via the
dentate stimulus electrode every 20 s, interleaved with single stimuli
every 10 s. Picrotoxin (100 μM), CGP–52432 (5 μM) and
D–(−)–2–amino–5–phosphonopentanoic acid (D–AP5, 50 μM) were al-
ways present in control ACSF and BRS–015 perfusion solutions.
Superfusion of slices with BRS–015 (100 μM) increased the amplitude
of dentate–evoked EPSCs. The eﬀect was fully reversible upon
switching from BRS–015 to ACSF solution (Fig. 2A). The consecutive
application of (2S,2′R,3′R)–2–(2′,3′–dicarboxycyclopropyl)glycine
(DCG–IV; 1 μM) had the opposite depressant eﬀect, consistent with the
high sensitivity of mossy ﬁbres to group II metabotropic glutamate
receptor agonists. The holding current (Iholding), paired–pulse ratio
(PPR) of EPSC amplitude and EPSC decay–time constant (τdecay), were
not altered by BRS–015 application (Fig. 2B–D). We also performed CV
(coeﬃcient of variation) analysis on evoked EPSCs. This type of ana-
lysis makes use of the inherent variability in synaptic responses over
many trials, which is caused by stochastic neurotransmitter release.
Changes in quantal size precisely change both the mean EPSC and the
variance such that the normalized ratio of mean2/variance, also known
as CV−2, remains constant. In contrast, changes in quantal content will
cause proportional changes of equal magnitude in both amplitude and
CV−2 ratios (Faber and Korn, 1991). The eﬀect of BRS-015 on the
variance of EPSCs can be visualized graphically by plotting the mean
EPSC amplitude against CV−2 (Fig. 2E). The potentiation of evoked
EPSCs by BRS–015 was accompanied by no change in the statistic
CV−2, consistent with increased quantal size. Next, we examined the
eﬀect of BRS–015 over a range of concentrations (1 nM–1mM) in order
to characterize the concentration–facilitation relationship (Fig. 2F).
Sub–micromolar concentrations of BRS–015 (0.1–1 nM) had no eﬀect
on EPSC amplitude, whereas BRS–015 (1 μM) only produced a minor
increase. BRS–015 (1mM) produced the largest increase in EPSC am-
plitude. Fitting of the concentration–facilitation relation with a logistic
function yielded an EC50 of 14.8 μM. These results conﬁrm our ob-
servations made with ﬁeld electrodes and highlight the dose–dependent
enhancing eﬀect of BRS–015 on NMDA receptor–independent neuro-
transmission at mossy ﬁbre synapses.
2.2. BRS–015 does not aﬀect kainate receptors or NMDA receptors
Because in our experiments NMDA receptors were blocked, we
asked the question whether the enhancing eﬀect of BRS–015 solely
involved AMPA receptors, kainate receptors, or both (Cossart et al.,
2002; Mulle et al., 1998; Vignes and Collingridge, 1997; Castillo et al.,
1997). We ﬁrst examined kainate receptor–mediated EPSCs in the
presence of GABA receptor blockers, D–AP5 (50 μM), and the
AMPA receptor antagonist 1–(4–aminophenyl)–3–methylcarba-
myl–4–methyl–3,4–dihydro–7,8–methylenedioxy–5H–2,3–benzodiaze-
pine (GYKI–53655, 50 μM). Superfusion of BRS–015 (100 μM) had no
eﬀect on kainate receptor–mediated EPSCs (Fig. 3A). In a separate set of
experiments, we recorded NMDA receptor–mediated EPSCs at
Vholding=+40mV, in the presence of picrotoxin (100 μM), CGP 52432
(5 μM) and 2,3–dioxo–6–nitro–1,2,3,4–tetrahydrobenzo[f]quinox-
aline–7–sulfonamide (NBQX, 20 μM). Although in these conditions
evoked EPSCs tended to run down, superfusion of BRS–015 (100 μM)
had no major eﬀect on their amplitude (Fig. 3B). Thus, neither NMDA
nor kainate receptor–mediated EPSCs were sensitive to BRS–015 im-
plying that it might selectively enhance AMPA receptors.
2.3. BRS–015 does not aﬀect basic electrical membrane properties
BRS–015–induced enhancement of transmission could result from
increased excitability of CA3 pyramidal neurons (e.g., via a global
change in Rinput). Hence, recordings were undertaken in current–clamp
mode to analyse possible changes in the basic electrical membrane
properties of neurons directly involved in the dentate–CA3 connection.
I–V relations were obtained in CA3 pyramidal neurons and granule cells
by delivering a series of hyperpolarizing and depolarizing current steps,
Fig. 1. Application of BRS–015 in stratum lucidum potentiates dentate–evoked
fEPSPs in CA3. In red is the fEPSP amplitude plotted against time showing a
rapid and reversible increase following the pressure application of BRS–015
(113.1 ± 22.8%, n=5, P=0.007). In black, no signiﬁcant increase in fEPSP
amplitude after local application of ACSF. Data are from 5 slices. Sample traces
show fEPSPs from one experiment (stimulus artifacts removed for clarity).
Picrotoxin (100 μM), CGP–52432 (5 μM) and D–AP5 (50 μM) are present in the
bathing solution. Arrow indicates the onset of BRS–015 or ACSF puﬀs. Circles
represent the mean fEPSP amplitude. Error bars: SEM. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
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in control condition, and in the presence of BRS–015 (Fig. 4). Super-
fusion of BRS–015 (100 μM) did not alter the membrane potential or the
Rinput of CA3 pyramidal neurons. In addition, BRS–015 had no eﬀect on
the ﬁring frequency (Fig. 4A,B). Similar conclusions were reached in
granule cells, where application of BRS–015 (100 μM) neither modiﬁed
the Rinput nor the membrane potential, the sag ratio or the maximum
ﬁring rate (Fig. 4C,D). Thus, BRS–015 does not promote the depolar-
izing and shunting eﬀect of a typical ionotropic glutamate receptor
agonist, implying that it does not directly activate a membrane con-
ductance.
2.4. BRS–015 potentiates glutamate–evoked currents in CA3 pyramidal
neurons
The results presented so far suggest that BRS–015 does not have
major presynaptic actions. Assuming that BRS–015 acts on postsynaptic
targets, it should enhance glutamate–evoked currents in CA3 pyramidal
neurons. We pressure–applied L–glutamate (100 μM) in the region of
the apical dendrite of a patched CA3 pyramidal neuron, and recorded
the resulting inward currents. GABA and NMDA receptors were blocked
with picrotoxin, CGP–52432 and D–AP5, respectively. As shown in
Fig. 2. Dose–dependent eﬀect of
BRS–015 at mossy ﬁbre synapses. A, Plot
of normalized EPSC amplitude against
time showing a reversible increase
(63.5 ± 12.5%, P=0.002) in the pre-
sence of BRS–015 (100 μM). Consecutive
application of the mGluRII agonist
DCG–IV (1 μM) depresses EPSCs by
70.7 ± 29.3% (P=0.01). Data pooled
from 5 neurons. Representative current
traces for each condition are shown on
top. B, No eﬀect of BRS–015 (100 μM)
on holding current (ΔIholding:
10.9 ± 7.4 pA, P=0.21). Horizontal
bar: mean. Error bars: SEM. C, BRS–015
(100 μM) does not alter the PPR (con-
trol: 1.89 ± 0.09 versus BRS–015:
1.78 ± 0.07, P=0.14). Sample traces
show consecutive paired EPSCs in con-
trol condition (black) and in the pre-
sence of BRS–015 (red). D, The EPSC
τdecay is not aﬀected by BRS–015 (con-
trol: 46.8 ± 3.7ms versus BRS–015:
43.9 ± 2.5ms, P=0.45). Example
traces show peak–scaled EPSCs from one
cell, in control condition (black) and in
the presence of BRS–015 (red). Each
paired circle represents data from one
experiment. E, in red is the mean frac-
tional change in CV−2 plotted against
the mean fractional change in EPSC
amplitude (BRS–015/baseline ratio of
CV−2=1.1 ± 0.1, n=5; P=0.9).
Error bars: SEM. Vectors represent frac-
tional changes in CV−2 and amplitude in
individual cells. Responses on the hor-
izontal (y=1) line depict changes in
EPSC amplitude without changes in
variance and therefore represent
changes in quantal size. The dashed grey
line is the 45° identity line. F,
Concentration–facilitation relation and
ﬁtting with a non–linear logistic func-
tion. BRS–015 (1 μM) produces a non–-
signiﬁcant increase in EPSC amplitude
(7.1 ± 6.5%, n=4, P=0.3). BRS–015
(10 μM) increases it by 35.2 ± 18.4%
(n=4, P=0.15) and BRS–015 (1mM)
by 87.5 ± 5.2% (n=4; P=4.E−4).
Error bars: SEM. Vertical dashed line
indicates the EC50. Picrotoxin (100 μM),
CGP–52432 (5 μM) and D–AP5 (50 μM)
are continuously present in the bathing
solution. (For interpretation of the re-
ferences to colour in this ﬁgure legend,
the reader is referred to the web version
of this article.)
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Fig. 5, superfusion of slices with BRS–015 (100 μM) reversibly increased
the amplitude of glutamatergic currents. The time course of the BRS-
015 enhancement of puﬀ-evoked glutamatergic currents developed
slowly and the eﬀect was smaller compared with the potentiation of
synaptic responses. Application of NBQX (20 μM) at the end of the ex-
periments largely reduced these currents indicating that they were
mostly mediated by AMPA receptors. These ﬁndings demonstrate that
the BRS–015 mediated enhancement of AMPA receptor function is in-
itiated in CA3 pyramidal neurons.
2.5. A single enantiomer of BRS–015 is active: comparison with piracetam
BRS–015 is obtained as a racemate following intramolecular acylal
cyclisation, yielding both the (+) and (−) enantiomers (Szulc et al.,
2015). The enantiomers were separated by chiral high performance
liquid chromatography (HPLC) and we investigated their eﬀects on
dentate–evoked fEPSPs. Superfusion of slices with (−) BRS–015
(100 μM) caused a reversible increase in fEPSP amplitude (Fig. 6A). In
contrast, (+) BRS–015 (100 μM) had no eﬀect on fEPSPs (Fig. 6B).
Application of the racemic mixture (+/−) BRS–015 (100 μM) pro-
duced a robust enhancement, the magnitude of which did not diﬀer
from that attained with (−) BRS–015 (Fig. 6C). We also tested the
nootropic drug piracetam. Piracetam (100 μM) was essentially inactive,
with only very high concentrations (500 μM) producing a modest in-
crease in fEPSP amplitude (Fig. 6C). These results indicate that the
active enantiomer (−) BRS–015 is a powerful enhancer of synaptic
transmission compared to the clinically relevant drug piracetam.
2.6. BRS–015 facilitates mossy ﬁbre LTP induction
Does the eﬀect of BRS–015 relate to LTP? We began addressing this
question by inducing LTP in slices incubated with the compound and
continuously superfused with it. Mossy ﬁbre inputs were monitored
with ﬁeld electrodes. Picrotoxin (100 μM), CGP–52432 (5 μM) and
D–AP5 (50 μM) were added to the perfusion solution to block GABAA,
GABAB, and NMDA receptors. NMDA receptor–independent LTP was
induced by long high–frequency stimulation delivered in stratum
granulosum (L–HFS). The magnitude of LTP in slices treated with
BRS–015 was signiﬁcantly smaller than that elicited in untreated slices
(Fig. 7A,B). We also performed experiments where BRS–015 was ap-
plied when mossy ﬁbre synapses were already undergoing LTP. In these
experiments, a second stimulus electrode was placed in the distal region
of stratum radiatum to activate associational/commissural (A/C) sy-
napses, acting as a control pathway. Application of BRS–015 (100 μM)
10min after induction of mossy ﬁbre LTP had no potentiating eﬀect on
dentate–evoked fEPSPs (Fig. 7C,D). Interestingly, BRS–015 did not af-
fect synaptic transmission at A/C synapses (Fig. 7C). Finally, instead of
using tetanic stimulation that induced saturating levels of LTP, we ap-
plied a milder tetanus and asked if application of BRS–015 could help it
in triggering LTP. As shown in Fig. 7F application of a high–frequency
stimulus burst in stratum granulosum (HFS1, 100 pulses for 1 s) caused
a transient increase in fEPSP amplitude that decayed to near baseline
level after 5 to 7min, akin to post–tetanic potentiation (PTP). Con-
secutive to PTP, the superfusion of slices with BRS–015 (100 μM) in-
creased the amplitude of dentate–evoked fEPSPs. Again, it had no eﬀect
on A/C responses indicating a degree of pathway selectivity. When a
second high–frequency stimulus burst (HFS2) was delivered in stratum
granulosum, the amplitude of fEPSPs measured 15min after HFS2 was
persistently increased, consistent with LTP. This larger and sustained
form of potentiation contrasted with the PTP elicited by HFS1. Alto-
gether, these results demonstrate that priming the tissue with BRS–015
facilitates LTP induction at mossy ﬁbre synapses. However, the mag-
nitude at which LTP is expressed in the presence of BRS–015 is smaller
when compared to LTP in untreated tissue.
2.7. Toxicity proﬁle of BRS–015 in stable cell lines
Toxicity studies were carried out in murine 3 T6 cells and human
HepG2 cells. BRS–015 was shown to be essentially non-toxic in the 3 T6
cell line (2mM maximum concentration, n=6) and exhibited an LD50
of 914 μM in the HepG2 cell line (n=6). This concentration was>
50–fold higher than the observed EC50 for enhancement of glutama-
tergic transmission. Thus, BRS–015 appears non–toxic to cells at
sub–millimolar concentration highlighting a good potential for phy-
siological and therapeutic applications.
3. Discussion
We have examined the eﬀects of a newly synthesized small molecule
on glutamatergic transmission and found a dose–dependent enhance-
ment of AMPA receptor–mediated signalling at mossy ﬁbre synapses.
We also showed that a single enantiomer was active and that the ra-
cemic mixture facilitated the induction of mossy ﬁbre LTP. Finally, we
Fig. 3. BRS–015 does not aﬀect kainate and NMDA receptor–mediated EPSCs.
A, Kainate receptor–mediated EPSCs isolated by adding picrotoxin (100 μM),
CGP–52432 (5 μM), D–AP5 (50 μM), and GYKI–53655 (50 μM) to the bathing
solution. Superfusion of slices with BRS–015 (100 μM) has little eﬀect on EPSC
amplitude (13.8 ± 7.7%, n= 5, P=0.17). Sample current traces are shown
on top (averages of 5 consecutive trials). B, Superfusion of BRS–015 (100 μM)
does not aﬀect NMDA receptor–mediated EPSCs (n= 9; P=0.75), whereas
application of DCG–IV (1 μM) depresses them by 92.2 ± 0.5% (n=6;
P=0.01). Each point represents the mean current amplitude. Error bars: SEM.
NBQX (20 μM), picrotoxin (100 μM) and CGP–52432 (5 μM) are present in the
bathing solution.
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found it non–toxic to cells emphasizing a good potential for further
chemistry and pre–clinical development.
3.1. BRS–015 enhancement of basal synaptic transmission
We report the eﬀect of BRS–015 in CA3 pyramidal neurons and
found that one consequence of its activity was increased AMPA EPSC
amplitude. This might have resulted from a number of steps directly or
indirectly enhancing AMPA receptor function. Indeed, the compound
spared kainate and NMDA receptors. However, we did not show a direct
modulation of AMPA receptors, as this would have required the pulling
of excised patches and fast application techniques. Nor can we rule out
(caption on next page)
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that metabotropic glutamate receptors may have contributed to the
BRS–015 induced enhancement, as these were left unblocked. We have
nevertheless several reasons to believe that BRS–015 modulated post-
synaptic sites, and ultimately AMPA receptors. Firstly, blocking AMPA
receptors with GYKI–53655 abolished the BRS–015 enhancement of
NMDA receptor–independent synaptic transmission. Second, the com-
pound had no eﬀect on the PPR and statistical CV−2 suggesting no
major change in glutamate release probability and quantal content
during the potentiation of transmission. (However, these measures
might not change detectably with modest increases in release prob-
ability given the high degree of variability observed with mossy ﬁbre
EPSCs.) Thirdly, BRS–015 potentiated non–NMDA currents evoked by
focal application of L–glutamate onto CA3 pyramidal cells, consistent
with a postsynaptic locus of action. Thus, BRS–015 did not show the
physiological signature of phorbol esters whose eﬀects are known to
enhance glutamate release (Honda et al., 2000; Kamiya et al., 1988;
Weisskopf et al., 1994). Nor did it mimic the previously described bi-
phasic eﬀect of kainic acid on mossy ﬁbre transmission to CA3 pyr-
amidal neurons (Schmitz et al., 2000, 2001).
The BRS-015 enhancement of puﬀ-evoked glutamatergic currents
was on average ~40% smaller than the potentiation of synaptic re-
sponses (fEPSPs or EPSCs). Such discrepancy could result from the fact
that pressure-applied L-glutamate activated a mixed population of re-
ceptors, some of which were insensitive to BRS-015. In support of this,
we found that BRS-015 was relatively ineﬃcient at A/C synapses.
Furthermore, the time course of enhancement during bath application
of BRS-015 was slow (5–10min) compared to rapid action (1–2min)
resulting from pressure-application of the compound (Fig. 5 versus
Fig. 1B). The rapid time course is consistent with quick delivery of the
compound in the region of synapses, as opposed to bath application,
which is expected to slowly build the concentration within the slice.
3.2. Putative mechanisms of action of BRS-015
So how could BRS–015 possibly work? It might be that BRS–015
binds to the AMPA receptor and stabilizes the channel in an open
conﬁguration, hence retarding the onset of receptor desensitization or
deactivation. Such a mechanism has been shown to underlie the actions
of aniracetam (Lawrence et al., 2003; Xiao et al., 1991; Isaacson and
Nicoll, 1991; Ito et al., 1990; Partin et al., 1996) and other AMPAkines
(Lauterborn et al., 2016; Arai et al., 2000). However, in stark contrast
with the latter benzamides, BRS–015 did not prolong τdecay of evoked
EPSCs, suggesting no major action on AMPA receptor desensitization.
Alternatively, BRS–015 could be enhancing the conductance of AMPA
receptors by means of phosphorylation leading to potentiation of sy-
naptic currents (Lisman et al., 2002). Indeed, neuronal AMPA receptors
contain stargazin–like auxiliary subunits known as transmembrane
AMPA receptor regulatory proteins (TARPs). TARPs mediate AMPA
receptor surface expression and synaptic clustering (Tomita et al.,
2006) and also modulate AMPA receptor channel gating by slowing
desensitization and deactivation (Tomita et al., 2005; Priel et al., 2005).
The recent evidence that Ca2+/calmodulin–dependent protein kinase II
(CaMKII) directly phosphorylates TARPγ–8 (Park et al., 2016) would
lend support to this notion of BRS–015 stimulation of kinase activity.
The compound would have to initiate a rise in postsynaptic Ca2+, either
via L–type Ca2+ channels (Yeckel et al., 1999; Wang et al., 2004; Kapur
et al., 1998), or following the release of Ca2+ from intracellular stores
and mitochondria. Interestingly, signalling pathways invoking the ac-
tivation of CaMKII or phospholipase C (PLC) and leading to phos-
phorylation of extracellular signal-regulated kinase (ERK) and cAMP
responding element–binding (CREB), are thought to underlie the noo-
tropic eﬀects of (−)-clausenamide (Chu et al., 2016; Tang and Zhang,
2004). Finally, BRS–015 could work via direct stimulation of kinase
activity or inhibition of phosphodiesterase activity leading to increased
AMPA receptor function. In particular, weak activation of protein ki-
nase A, which shows a similar degree of synaptic speciﬁcity and eﬀect
on EPSC amplitude, could underlie some of the eﬀect of BRS-015.
The lack of eﬀect of BRS–015 on stratum radiatum evoked responses
remains puzzling. It could reﬂect a distinct AMPA receptor subunit
composition between mossy ﬁbre and A/C synapses, or diﬀerent levels
of basal phosphorylation of AMPA receptors. Asymmetrical synapses
between large mossy ﬁbre terminals and thorny excrescences in CA3
pyramidal neurons contain an average number of AMPA receptors ex-
ceeding 4 times the number reported for C/A synapses (Fabian-Fine
et al., 2000; Nusser et al., 1998). There is also a diﬀerence in the
variability of receptor content, with mossy ﬁbre synapses having the
smaller variability, whereas C/A synapses can be void of AMPA re-
ceptors (Nusser et al., 1998; Kullmann, 1994; Liao et al., 1995).
Fig. 4. BRS–015 does not aﬀect the electrical membrane properties of CA3 pyramidal neurons and dentate granule cells. A, Voltage deﬂections recorded in a CA3
pyramidal neuron in response to hyperpolarizing and depolarizing current steps (−20–50 pA, 1 s), in control condition (black) and in the presence of BRS–015
(100 μM, red). There are no signiﬁcant changes in membrane potential, Rinput, rheobase current, and ﬁring. B, Summary data for membrane potential (control:
−67.7 ± 3.6mV versus BRS–015: −62.9 ± 3.9mV, P=0.2); Rinput (control: 206.7 ± 19.5MΩ versus BRS–015: 171.7 ± 17.3MΩ, P=0.053); rheobase current
(control: 35.7 ± 5.7 pA versus BRS–015: 35.7 ± 4.8 pA); mean ﬁring frequency (control: 7.4 ± 0.8 Hz versus BRS–015: 7.1 ± 0.7 pA); maximum ﬁring frequency
(control: 12.2 ± 1.5 Hz versus BRS–015: 13.5 ± 2.1 Hz, P=0.21). Data pooled from 7 neurons. C, Voltage deﬂections recorded in a dentate granule cell in response
to hyperpolarizing and depolarizing current steps (−20–50 pA, 1 s), in control condition (black), and in the presence of BRS–015 (100 μM, red). Note the presence of
a “sag” at hyperpolarized potential (asterisk). D, Summary data for membrane potential (control: −81.8 ± 1.1mV versus BRS–015: −78.8 ± 2.1mV, P=0.2);
Rinput (control: 246.4 ± 18.9MΩ versus BRS–015: 212.8 ± 27.6MΩ, P=0.15); sag ratio (control: 0.99 ± 0.01 versus BRS–015: 0.99 ± 0.03 pA, P=0.83);
maximum ﬁring frequency (control: 102.2 ± 2.1 Hz versus BRS–015: 101.6 ± 1.5 Hz, P=0.66). Data pooled from 5 granule cells. Each circle represents the data
from one experiment. Horizontal bar: mean. Error bars: SEM. The bathing solution contains picrotoxin (100 μM), CGP–52432 (5 μM) and D–AP5 (50 μM). (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 5. BRS–015 potentiates glutamate–evoked currents in CA3 pyramidal
neurons. Amplitude of puﬀ–evoked glutamatergic currents plotted against time
showing a reversible increase (57.6 ± 15.2%, n=4, P=0.03) in the presence
of BRS–015 (100 μM). Application of NBQX (20 μM) at the end of the experi-
ment strongly depresses the currents, leaving a small residual component.
Traces on top show glutamatergic currents (single trials) from one neuron, in
control condition and in the presence of BRS–015 (100 μM). Glutamate puﬀ:
5–20 psi, 10–50ms, every 60 s (grey circle). Error bars: SEM.
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Furthermore, although the AMPA receptor subunits GluA1–GluA4 are
enriched both at A/C and mossy ﬁbre synapses, higher levels of ex-
pression of GluA1 have been reported for A/C synapses (Baude et al.,
1995). The number and variability in AMPA receptor expression is thus
remarkably diﬀerent at these two functionally distinct synapse popu-
lations, which could explain some of the speciﬁcity in the eﬀect of
BRS–015.
3.3. Comparison between BRS-015 and clausenamide
Naturally occurring clausenamide is in racemic form, and like BRS-
015, it acts as a LTP enhancer (Chu and Zhang, 2014; Chu et al., 2016;
Xu et al., 2005). Both compounds are roughly equiactive with EC50
values in the range of 10–20 μM. There are four chiral centres in
clausenamide implying that sixteen stereoisomers can occur (Xu et al.,
2005). The single asymmetry centre of BRS-015 seems to be a clear
advantage in this regard, oﬀering a much simpler strategy in search for
analogues. In addition, (−)-clausenamide crosses the blood brain bar-
rier and conveys most biological activity, whereas (+)-clausenamide is
inactive (Ning et al., 2012). Our compound shows strikingly similar
stereo-selectivity but we do not know whether it penetrates the brain if
administered in vivo. Finally, (−)-clausenamide is far more active than
the nootropic drug piracetam (Chu et al., 2016), and so is BRS-015
(Fig. 6).
A major diﬀerence with clausenamide, however, is that 100 μM
BRS-015 racemate mixture was found equiactive with the (−) BRS-015
isomer. In the case of clausenamide, the (−) isomer is 5–10 time more
active than its racemic form (Chu et al., 2016). This discrepancy sug-
gests that 100 μM (−)-BRS-015 caused a near-to-saturating potentia-
tion of synaptic transmission. Only a full dose-response relationship for
the (−)-BRS-015 isomer will enable a meaningful comparison with the
racemic form of this compound.
3.4. BRS–015 induces a short–to–long term plasticity switch
We have further shown that mossy ﬁbre LTP in the presence of
BRS–015 was smaller than in untreated tissue, and that the compound
was ineﬀective on synaptic responses exhibiting LTP. These observa-
tions suggest that mossy ﬁbre LTP and the putative signalling pathways
engaged by BRS–015 compete for a common pool of signalling mole-
cules or proteins. However, in contrast to our compound, several groups
have reported enhanced LTP in the CA1 region following AMPAkine
treatment (Xiao et al., 1991; Arai et al., 2000; Arai and Lynch, 1998;
Staubli et al., 1992). This diﬀerence with our study could be the result
of diﬀerent stimulation protocols used for inducing LTP (L–HFS versus
theta–burst) in diﬀerent hippocampal areas (CA1 versus CA3). It could
also be related to the age of animals, and diﬀerent levels of LTP ex-
pressed at diﬀerent developmental stages. Finally, we demonstrated
that tetanic stimulation eliciting PTP at mossy ﬁbre synapses (Henze
et al., 2002; Vyleta et al., 2016) was capable of triggering LTP once the
compound had potentiated basal glutamatergic transmission. How this
occurred remains unclear, but the postsynaptic enhancement of AMPA
receptors by BRS–015 could be paramount to this plasticity switch.
Noteworthy, several studies have shed light on the importance of
postsynaptic Ca2+, mGluRs, and ephrin signalling in this phenomenon
(Yeckel et al., 1999; Wang et al., 2004; Kapur et al., 1998; Armstrong
et al., 2006; Contractor et al., 2002). It is thus conceivable – albeit
speculative – that our compound promotes a form of chemical plasticity
via postsynaptic modiﬁcations enhancing AMPA receptor function, or
leading to the insertion of new AMPA receptors at postsynaptic den-
sities (Sinnen et al., 2017).
Together, these data unravel a novel small molecule with a strong
and reversible enhancing eﬀect on AMPA receptor–mediated synaptic
transmission. The eﬀect was speciﬁc to mossy ﬁbre synapses where the
compound facilitated the induction of LTP. Our lead molecule thus
demonstrates surprising and unexpected activity as enhancer of dentate
gyrus inputs into the hippocampus, which may be useful in the treat-
ment of memory related disorders.
Fig. 6. (−) BRS–015 is more potent than piracetam at low concentration. A,
Plot of EPSP amplitude against time showing an increase (51.8 ± 15.1%,
n= 6, P=0.02) in the presence of (−) BRS–015 (100 μM). The consecutive
application of DCG–IV (1 μM) depresses fEPSPs by 91.1 ± 7.2% (n=5;
P=2E−4). Example voltage traces from one experiment are shown on top for
each condition (stimulation artifacts truncated for clarity). B, Superfusion of
(+) BRS–015 (100 μM) has no signiﬁcant eﬀect on fEPSP amplitude. DCG–IV
(1 μM) depresses fEPSPs by 83.9 ± 11.3% (n=5; P=0.04). Sample traces
show fEPSPs from one experiment (stimulus artifact removed for clarity). C,
Summary data for (+/−) BRS–015 (100 μM): 49 ± 18.9%, n= 5, P=0.04;
DMSO 0.1%: 1.7 ± 2.2%, n= 2; piracetam (100 μM): 2.3 ± 6.7%, n=3;
piracetam (500 μM): 26.5 ± 10.1%, n=3, P=0.11; (+) BRS–015 (100 μM):
0.2 ± 3.2%, n=5, and (−) BRS–015 (100 μM): 51.8 ± 15.1%, n=6,
P=0.02. Error bars: SEM. *, P < 0.05, paired t–test.
B.R. Szulc et al. Molecular and Cellular Neuroscience 92 (2018) 82–92
88
4. Materials and methods
4.1. Electrophysiology
All experiments were performed on male Sprague Dawley rats
(Harlan Laboratories Ltd., Oxon, UK), aged postnatal day 21–40. This
study was performed in accordance with the Animals (Scientiﬁc
Procedures) Act 1986. Animals were placed inside a chamber saturated
with an isoﬂurane/O2 mixture and anesthetized. The level of anaes-
thesia was tested by a paw pinch. After decapitation, the brain was
(caption on next page)
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removed and kept in ice–cold dissecting solution. Transverse hippo-
campal slices (300 μm) were obtained using a vibratome (Leica,
VT–1200S). Slices were stored at 35 °C for 30min after slicing and then
at 22 °C. For the dissection and storage of slices, the solution contained:
NaCl (87mM), NaHCO3 (25mM), glucose (10mM), sucrose (75mM),
KCl (2.5 mM), NaH2PO4 (1.25mM), CaCl2 (0.5 mM) and MgCl2 (7 mM).
During experiments, slices were superfused with artiﬁcial cere-
bro–spinal ﬂuid solution (ACSF) containing: NaCl (125mM), NaHCO3
(25mM), glucose (25mM), KCl (2.5 mM), NaH2PO4 (1.25mM), CaCl2
(4 mM) and MgCl2 (4 mM), equilibrated with 95% O2/5% CO2. The
divalent cation concentrations were kept high to suppress polysynaptic
transmission. The osmolarity and pH of perfusion solutions were ad-
justed to ~320mOsmol/L and 7.3, respectively. All recordings were
performed at 21 °C. A slice was transferred into the recording chamber
and visualized with an Olympus BX 51WI microscope (Olympus Europa
Holding GmbH, Hamburg, Germany) connected to a KPM–3 Hitachi
infrared video camera. A bipolar stimulating electrode (FHC Inc.,
Bowdoin, Maine, USA) was positioned under low magniﬁcation (10×)
in the supra–granular blade of the dentate gyrus to activate mossy ﬁbre
synapses every 10–20 s using constant current (0.3–1.5 μA, 50–200 μs
square pulses). To set the intensity of stimulation an input-output (I/O)
relation was obtained for each slice when applying the control perfu-
sion solution. The stimulus intensity was set such that the amplitude of
the test fEPSP reached 30–40% of maximum amplitude based on the I/
O curve. Similar stimulation intensities were used for regular testing of
fEPSPs (Figs. 1, 6) and for HFS (Fig. 7). Two–pathway experiments were
performed by positioning a second stimulating electrode in the distal
part of stratum radiatum in CA3 to activate A/C synapses. A pipette
ﬁlled with ACSF was inserted in stratum lucidum of the CA3 sub–region
to record fEPSPs in response to electrical stimulation in the dentate
gyrus. For two–pathway experiments, interleaved fEPSPs were recorded
at one or the other pathway. Synaptic responses were recorded with an
Axopatch 200B ampliﬁer (Molecular Devices), ﬁltered at 2 kHz (in-
ternal 4–pole low–pass Bessel ﬁlter), and sampled at 10 kHz. Two tests
were routinely applied to verify that the signal recorded in stratum
lucidum was a mossy ﬁbre fEPSP. First, increasing the stimulation
frequency caused pronounced facilitation (> 2.5–fold at 1 Hz at room
temperature). Second, application of the group II mGluR agonist
DCG–IV (1 μM) depressed the fEPSP amplitude to<20% of control
fEPSP (Salin et al., 1996).
For patch–clamp experiments, neurons were visualized under in-
frared–diﬀerential interference contrast (DIC) imaging with a water–-
immersion high–magniﬁcation (60×) objective (Olympus) and a
four–fold magniﬁcation changer (Luigs & Neumann GmbH, Ratingen,
Germany). The pipette solution used for voltage–clamp recordings
contained: CsCl (120mM), QX314–Br (5mM), NaCl (8 mM), MgCl2
(0.2 mM), HEPES (10mM), EGTA (2mM), MgATP (2mM), Na3GTP
(0.3 mM), at pH 7.2 and osmolarity 310mOsm/L. The pipette solution
used for current–clamp recordings contained: 135mMK–gluconate,
5 mM KCl, 1 mM CaCl2, 5 mM EGTA–Na, 10mM HEPES, 10mM
glucose, 5 mM MgATP, and 0.4mM Na3GTP. The access resistance,
monitored throughout the experiments, was< 20MΩ and results were
discarded if it changed by>20%. Junction potentials were not cor-
rected. For glutamate puﬀs, L–glutamate (100 μM in ACSF) was applied
at 5–20 psi (10–50ms). Puﬀs were applied every 60 s to allow for glu-
tamate clearance. The puﬀ electrode was positioned at the border be-
tween strata lucidum and radiatum, 100–150 μm away from the soma
of the recorded CA3 pyramidal cell, and along its apical dendrite. Mossy
ﬁbre LTP was induced by long high–frequency tetanic stimulation
(L–HFS) represented by 100 pulses in 1 s, 3 times, separated by 10 s.
Slices in which LTP experiments were performed in the presence of
BRS–015 were maintained within an interface chamber on a Petri dish
containing BRS–015 solution (100 μM) for at least 2 h prior to re-
cording, and were continuously superfused with it before and after LTP
induction (Fig. 7A,B).
4.2. Data analysis and statistics
For each recording, fEPSP or EPSC amplitude was normalized to the
amplitude measured 1–3min pre–drug application. The overall change
in amplitude for ‘n’ recorded neurons was determined by averaging
normalized amplitudes, then expressed as a percentage. EPSC decay–-
time constant was obtained by ﬁtting the average of 5–10 consecutive
trials in control condition and in the presence of BRS–015 with a single
exponential function using Matlab R2010a (TheMathWorks, version
7.10). For PPR measurements of EPSC amplitude at −60mV, inter-
leaved responses evoked by a single stimulus were subtracted from
those elicited by paired stimuli (20ms apart). PPR was determined by
dividing the peak amplitude of EPSC2 by that of EPSC1. 1/CV2 was
calculated as (mean EPSC)2 / (VarEPSC− Varnoise). For each neuron re-
corded in current–clamp mode, the I–V relation was determined by
measuring the amplitude of steady state voltage deﬂections elicited by a
series of hyperpolarizing and depolarizing current steps (−120 pA to
+100 pA; 500ms). The mean ﬁring frequency was calculated by di-
viding the number of action potentials by the duration of a supra–-
threshold current step that did not inactivate Na+ channels
(400–700 pA, 500ms). The maximum ﬁring rate was determined by the
time interval between the ﬁrst and second action potentials. Rinput was
obtained by ﬁtting the linear portion of the I–V relation at hyperpo-
larized potentials. ‘Sag’ ratios were determined as the ratio between the
steady state voltage and peak voltage in response to a current injection
that resulted in a membrane potential negative to −120mV. Unless
otherwise noted, we routinely applied a two–tailed paired t–test to test
the diﬀerence between the sampled means (Gaussian data scatter). The
conﬁdence intervals were calculated using OriginPro (Originlab). Data
were considered signiﬁcant if P < 0.05. Sample traces from example
recordings were obtained by averaging 5–10 consecutive trials in con-
trol condition, and 5–10min after the debut of the application of a
given drug (except for Figs. 4A,C and 5). Values are given as mean ±
SEM. Error bars represent SEM.
Fig. 7. BRS–015 induced modulation of mossy ﬁbre LTP. A, Time course of normalized fEPSP amplitude in slices continuously superfused with BRS–015 (100 μM,
red) and in untreated slices (black), and depression by the mGluR II agonist DCG–IV (1 μM). There is a reduced mossy ﬁbre LTP in the presence of BRS–015 (100 μM).
B, Cumulative probability distribution of mossy ﬁbre LTP measured as the percentage of fEPSP potentiation 15–20min after tetanus compared with control period.
LTP in slices treated with BRS–015 (111.51 ± 16.81%, n= 6) is smaller than that elicited in untreated slices (182.9 ± 20.4%, n= 8, P=0.02). *, unpaired t–test.
C, Time course of normalized fEPSP amplitude showing a non–signiﬁcant increase (17.9 ± 13.5%, n= 4, P=0.2) when BRS–015 (100 μM) is applied during mossy
ﬁbre LTP. fEPSPs elicited by stratum radiatum stimulation remain largely unaﬀected (13.3 ± 14.9% reduction, n=4, P=0.19). Addition of DCG–IV (1 μM)
depresses fEPSPs evoked by stratum granulosum (s. g.) stimulation (70.9 ± 7.4%, n=4, P=0.03) but has no eﬀect on stratum radiatum (s. rad) evoked responses.
Arrow indicates the time of tetanic stimulation. D, Example traces from a single experiment depicted in panel C. E, Normalized fEPSP amplitude plotted against time
showing PTP of fEPSPs (57.9 ± 12.7%, n= 11) after a stimulus burst is delivered in stratum granulosum (HFS1, 100 stimuli in 1 s). Subsequent superfusion with
BRS–015 (100 μm) increases the amplitude of fEPSPs by 48.4 ± 9.6% (n= 11, P=0.05). It has no eﬀect on stratum radiatum evoked responses (6.2 ± 7.6%,
n= 5, P=0.3). Blue arrow indicates the time of a stimulus intensity reset at the dentate electrode when the enhancing eﬀect of BRS–015 reaches a plateau. A second
stimulus burst (HFS2, identical to HFS1) delivered after 20min of application of BRS–015 leads to early LTP (174.3 ± 15.1%, n=6, P=0.04). Final application of
DCG–IV (1 μM) depresses stratum granulosum evoked fEPSPs by 82.8 ± 3.8% (n=4, P=0.008) and has no eﬀect on those elicited by stratum radiatum stimu-
lation. Each point represents the mean. Error bars: SEM. Picrotoxin (100 μM), CGP–52432 (5 μM) and D–AP5 (50 μM) are included in the perfusion solution. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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4.3. Toxicity assays
10,000 CRFK cells were eluted with Roswell Park Memorial Institute
(RPMI) 1640 medium supplemented with 10% fetal bovine serum
100M/mL Glutamine and 1% v/v antibiotic/antimycotic (Gibco) onto
96–well plates and incubated for 24 h at 37 °C (5% CO2). The medium
was then removed by vacuum and replaced with the speciﬁc dilution
(1 nM–1mM) to test the toxicity (3× 200 μL). BRS–015 (1 nM–1mM)
was then suspended in 2% di–methylsulfoxide (DMSO) and RPMI 1640
medium supplemented with 10% fetal bovine serum 100M/mL
Glutamine and 1% v/v antibiotic/antimycotic, and diluted to the de-
sired concentrations. After 24 h, the wells were observed and the
medium removed. The cells were then suspended in RPMI 1640 phenol
red–free medium (180 μL) and 3–(4,5–dimethylthiazol–2–yl)–2,5–di-
phenyltetrazolium bromide (MTT) (3mg/mL), and incubated 4 h at
37 °C (5% CO2). The medium was then removed by vacuum and the
cells were lysed with methanol (200 μL) to reveal a bright purple for-
mazan product. The methanol–formazan absorbance was then de-
termined at 570 nm using a BioTek Synergy HT plate reader with KC4
software. Data were expressed as the percentage of viability (normal-
ized to cells with no exposure) of compound–treated wells compared to
that of untreated control wells.
4.4. Drugs and chemicals
Picrotoxin was purchased from Abcam Biochemicals (Cambridge,
UK) and prepared in DMSO for use at a ﬁnal concentration of 100 μM.
BRS–015 was prepared in DMSO at a stock concentration of 50mM.
DCG–IV, CGP–52432, and NBQX were purchased from Tocris
Bioscience (Bristol, UK). L–glutamic acid, D–AP5 and GYKI 53655 were
purchased from Abcam Biochemicals (Cambridge, UK). All other che-
micals used for the synthesis of BRS–015 can be sourced in Szulc et al.
(2015).
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.mcn.2018.07.003.
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